Alcohol
Volume 25, Issue 2 , Pages 115-122, October 2001

No effect of the cortisol-synthesis inhibitor metyrapone on alcohol drinking: a pilot study

  • Matts Eriksson

      Affiliations

    • Institute of Clinical Neuroscience, Section of Psychiatry, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden
  • ,
  • Claudia Fahlke

      Affiliations

    • Department of Psychology, Göteborg University, SE-405 30 Göteborg, Sweden
    • Corresponding Author InformationCorresponding author. Department of Psychology, Göteborg University, P.O. Box 500, SE-405 30 Göteborg, Sweden. Tel.: +46-31-7734289; fax: +46-31-7734628
  • ,
  • Stefan Hansen

      Affiliations

    • Department of Psychology, Göteborg University, SE-405 30 Göteborg, Sweden
  • ,
  • Ulf Berggren

      Affiliations

    • Institute of Clinical Neuroscience, Section of Psychiatry, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden
  • ,
  • Per Mårin

      Affiliations

    • Institute of Heart and Lung Diseases, Sahlgren University Hospital, SE-431 45 Göteborg, Sweden
  • ,
  • Jan Balldin

      Affiliations

    • Institute of Clinical Neuroscience, Section of Psychiatry, Sahlgren University Hospital/Mölndal, SE-431 80 Mölndal, Sweden

Received 14 September 2000; received in revised form 25 April 2001; accepted 25 June 2001.

Abstract 

Two bases for this study were the theory of stress as a provoking factor for high alcohol consumption in human being and findings that the stress hormones stimulate ethanol intake in rats. We therefore investigated whether the cortisol-synthesis inhibitor metyrapone could reduce high alcohol consumption in socially stable subjects who reported drinking mainly for relaxation purposes. Most of the investigated subjects were found to be alcohol dependent (81%), with moderately high levels of intake, yet they had not reported more severe life problems. All subjects reported their daily alcohol consumption during 2-week baseline, medication, and postmedication periods. Sixteen subjects were given 1 g of metyrapone orally daily for 14 days, and 15 subjects received placebo. Morning serum cortisol concentration was assessed four times in the course of the study period. Metyrapone treatment was not found to reduce alcohol consumption more than placebo. Serum cortisol concentrations remained within the laboratory reference interval during the study and did not differ between the study groups. In this study, we found that a cortisol-synthesis inhibitor had no effect on alcohol consumption. One reason may be that cortisol secretion has no role in the maintenance of high alcohol consumption. On the other hand, because this study is the first of its kind, further studies using other doses of treatment and treatment schedules are suggested.

Keywords:  Alcoholism, Cortisol, Metyrapone, Treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0741-8329(01)00173-2

Alcohol
Volume 25, Issue 2 , Pages 115-122, October 2001